tradingkey.logo

BRIEF-Palvella Therapeutics To Expand Phase 3 Selva Clinical Trial Of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin)

ReutersFeb 10, 2025 1:10 PM

- Palvella Therapeutics PVLA.O:

  • PALVELLA THERAPEUTICS TO EXPAND PHASE 3 SELVA CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS TO INCLUDE THE YOUNGER PEDIATRIC POPULATION, CHILDREN 3 TO 5 YEARS OLD

  • PALVELLA THERAPEUTICS INC - TO REPORT PHASE 3 TRIAL RESULTS IN Q1 2026

Source text: ID:nGNX6B2g7s

Further company coverage: PVLA.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI